Theophilus Eugenia H, Hayes Johnnie R, Potts Ryan J, Ayres Paul H, Williams Chandra D, Garner Charles D
Research and Development, R. J. Reynolds Tobacco Company, Bowman Gray Technical Center, Winston-Salem, NC 27105, USA.
Exp Toxicol Pathol. 2012 Jan;64(1-2):15-24. doi: 10.1016/j.etp.2010.05.013. Epub 2010 Jun 23.
This manuscript presents data from 90-day toxicology studies designed to characterize the subchronic effects of a smokeless tobacco blend and an aqueous extract of that blend when administered to rodents in NTP-2000 feed. Positive control (nicotine tartrate) and treatment groups were matched for a range of nicotine levels. The doses evaluated were 0.3, 3, and 6 mg nicotine/kg body weight/day in Wistar Hannover rats and 6, 60, and 120 mg nicotine/kg/day in CD-1 mice. Variables evaluated included plasma nicotine and cotinine, body weights, feed consumption, clinical observations, clinical and anatomic pathology (including organ weights), and histopathology. Plasma nicotine and cotinine levels were dose-responsive. Key effects such as body weight reductions and organ weight changes occurred in rats and mice predominantly at the highest doses of test articles and positive control in the absence of treatment-related gross or histopathological changes. Organ weight changes were attributed mainly to the lower body weights of treated vs. control groups. The blend- and extract-induced effects generally paralleled each other and the nicotine-induced effects. Based on these studies, the doses evaluated spanned the no observable adverse effect level, the lowest observable adverse effect level and the maximum tolerated dose.
本手稿展示了来自90天毒理学研究的数据,这些研究旨在表征无烟烟草混合物及其水提取物在以NTP - 2000饲料喂给啮齿动物时的亚慢性效应。阳性对照(酒石酸尼古丁)和治疗组在一系列尼古丁水平上进行了匹配。在Wistar Hannover大鼠中评估的剂量为0.3、3和6毫克尼古丁/千克体重/天,在CD - 1小鼠中为6、60和120毫克尼古丁/千克/天。评估的变量包括血浆尼古丁和可替宁、体重、饲料消耗、临床观察、临床和解剖病理学(包括器官重量)以及组织病理学。血浆尼古丁和可替宁水平呈剂量反应关系。在大鼠和小鼠中,主要在受试物和阳性对照的最高剂量下出现体重减轻和器官重量变化等关键效应,且无与治疗相关的大体或组织病理学变化。器官重量变化主要归因于治疗组与对照组相比体重较低。混合物和提取物诱导的效应通常彼此平行,且与尼古丁诱导的效应相似。基于这些研究,评估的剂量涵盖了无明显不良作用水平、最低明显不良作用水平和最大耐受剂量。